(CercleFinance.com) – GenSight Biologics announces that it has signed a subscription agreement for an amount of 12 million euros in the form of a bond issue convertible into shares with Heights Capital, whose settlement-delivery is scheduled for December 28 .
‘This new financing will enable us to secure an additional 12 million under conditions that will again not be dilutive for our shareholders, despite particularly difficult market conditions’, declared Thomas Gidoin, administrative and financial director.
‘These bonds are convertible with a premium of 30% on the current price, and redeemable in shares with a maximum discount of 15% on the current price, with the possibility of repaying in cash’, he specifies.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
